CD38 and plasma cell myeloma: Anti-CD38 monoclonal antibodies, such as daratumumab, have been previously demonstrated to induce a substantial depletion of plasma cells in the bone marrow of patients with refractory multiple myeloma [20,21], and are currently used in clinical practice.